Ventyx Biosciences Announces Participation in Healthcare Conference
SAN DIEGO — Ventyx Biosciences, Inc. (Nasdaq: VTYX), a leading clinical-stage biopharmaceutical company, is excited to share its participation in an engaging fireside chat at the highly anticipated Piper Sandler 37th Annual Healthcare Conference.
Key Details of the Conference
The fireside chat is set for Wednesday, December 3, and will take place from 4:00 to 4:25 PM ET. This event presents an excellent opportunity for stakeholders and industry enthusiasts to hear about the latest advancements and initiatives being pursued by Ventyx.
Understanding Ventyx Biosciences’ Mission
Ventyx Biosciences focuses on pioneering innovative oral treatments aimed at patients suffering from inflammation-mediated cardiovascular and neurodegenerative diseases. With a strong background in medicinal chemistry, structural biology, and immunology, the company is at the forefront of discovering unique oral small molecule therapeutics addressing significant unmet medical needs.
Innovative Drug Candidates
Ventyx's portfolio proudly features a range of NLRP3 inhibitors, with VTX2735 currently in Phase 2 development for recurrent pericarditis. Another notable candidate is VTX3232, a CNS-penetrant NLRP3 inhibitor, which just completed its Phase 2 study targeting obesity and cardiovascular risk and a Phase 2a study for individuals with Parkinson’s disease.
Expanding Therapeutic Horizons
Ventyx is also actively working on a solid pipeline for inflammatory bowel disease, with two compounds in Phase 2 studies: tamuzimod (VTX002), an S1P1R modulator, and VTX958, which is a TYK2 inhibitor. These developments emphasize the company's commitment to addressing challenging health conditions through effective therapies.
Stay Updated with Ventyx
For those interested in following the latest updates from Ventyx Biosciences, the company encourages visits to its official website. A live webcast of the upcoming conference will be available on their site, enabling investors and interested parties to stay informed. A replay of the session will also be accessible for 30 days post-event.
Frequently Asked Questions
What is the purpose of Ventyx’s participation at the conference?
The participation aims to provide insights into their innovative therapies and engage with stakeholders in the healthcare sector.
When will the fireside chat at the conference take place?
The chat is scheduled for December 3, from 4:00 to 4:25 PM ET.
How can I access the live webcast of the event?
The live webcast will be available on the Ventyx Biosciences website under the Investors and News section.
What types of therapies is Ventyx developing?
Ventyx is developing oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases, including a portfolio of NLRP3 inhibitors.
Who can I contact for investor relations inquiries?
For investor relations, you can reach Alex Schwartz, Vice President, at Ventyx Biosciences via email at IR@ventyxbio.com.